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Case presentation
A previously healthy 20-year-old male was admitted to the University
of Tokyo Hospital because of weakness in his legs and transient
syncope during a marathon that day. The ambient temperature was
21.8°C, and the relative humidity was 60%. The patient took part in the
race despite having symptoms of a common cold; he had taken no
medication. Complaining of weakness in his legs, he collapsed after
having run approximately 7 km. At that time, he was reportedly
disoriented and slightly confused. Profuse sweating was observed.
Physical examination at the hospital showed that he was alert and
oriented but had mild amnesia. He complained of diarrhea and severe
thirst. Body temperature was 39.1°C; blood pressure, 106/60 mm Hg;
pulse, 130 to 150/mm; and respiratory rate, 54/mm. Examination of the
eyes, heart, lungs, abdomen, and extremities was unremarkable. Patel-
lar and Achilles tendon reflexes were suppressed slightly. An electro-
cardiogram showed sinus tachycardia and was otherwise normal. The
urine was dark brown and benzidine positive. The urine osmolality was
222 mOsm/kg H20; pH was 6.0. Proteinuria, 1+ glucosuria, and
microhematuria were present. The urine sodium concentration was 56
mEq/liter, and the urine creatinine concentration was 19.5 mg/dl. Serum
electrolyte evaluation showed: sodium, 141 mEq/liter; potassium, 3.0
mEq/liter; chloride, 101 mEq/liter; calcium, 11.0 mg/dl. Other labora-
tory studies revealed: serum total protein, 9.0 g/dl; glucose, 80 mg/dl;
creatinine, 2.7 mg/dl; and BUN, 20 mg/dl. Glutamic oxalacetic transam-
inase (GOT) and lactic dehydrogenase (LDH) activities, measured in
the same blood sample, were 84 KU (Karmen units) and 936 lU/liter,
respectively. The patient was given 1.5 liters of saline intravenously
during the first several hours in the hospital.
The following day the patient complained of pain in the thighs, but no
muscle swelling was apparent. Body temperature was 37.3°C; blood
pressure, 140/72 mm Hg; and pulse, 80/mm. Urine output was 500 ml/
day. Myoglobin was detected in the serum and urine, and myosin was
found in the serum. Laboratory examination disclosed the following:
hematocrit, 45.0%; hemoglobin, 14.7 g/dl; red blood cell count,
4,960,000/mm3; white blood cell count, 12,000/mm3, of which 75% were
neutrophils; platelets, 94,000/mm3; prothrombin time, 63%; serum total
protein, 7.6 g/dl; albumin, 4.4 g/dl; plasma fibrinogen, 389 mg/dl;
haptoglobin, 170 mg/dl; fasting blood sugar, 80 mg/dl; serum sodium,
136 mEq/liter; potassium, 3.0 mEq/liter; chloride, 99 mEq/liter; arterial
blood pH, 7.27; calcium, 9,6 mg/dl; phosphorus, 3.3 mg/dl; BUN, 28
mg/dl; serum creatinine, 4.3 mg/dl; uric acid, 12 mg/dl; GOT, 208 KU;
glutamic pyruvic transaminase (GPT), 79 KU; LDH, 1776 lU/liter with
predominant isoenzyme type 5. The creatinine phosphokinase (CPK)
activity in the serum was too high to measure. Neither fibrin nor
fibrinogen degradation products (FDP) were detected in the serum or
urine. Plasma renin activity was not measured.
Thereafter, BUN and serum creatinine levels increased, although
urine output remained between 700 and 1000 ml/day. On the fifth
hospital day the following laboratory values were obtained: BUN, 90
mg/dl; serum creatinine, 14.5 mg/dl; GOT, 638 KU; GPT, 171 KU;
LDH, 2000 lU/liter; and CPK, 292 lU/liter. Serum sodium was 139
mEq/liter and serum potassium was 4.6 mEq/liter. Prothrombin time
was 100%. Potassium exchange resins were administered to prevent
hyperkalemia. On the ninth hospital day, the BUN reached 136 mg/dl
and the serum creatinine increased to 19.3 mg/dl. The serum sodium
concentration fell to 128 mEq/liter and the calcium level to 6.6 mg/dl.
Potassium increased to 6.3 mEq/liter despite daily administration of the
resins. Serum phosphate concentration was 10.6 mg/dl, and the serum
uric acid concentration was 18.4 mg/dl.
Peritoneal dialysis was initiated. Approximately 8 days later, polyuria
appeared and within 9 more days the BUN fell to 13 mg/dl, serum
creatinine to 2.2 mg/dl, and uric acid to 3.6 mg/dl. The forearm ischemic
test, performed after renal function had returned to normal, disclosed
an appropriate elevation in serum lactate concentration. The patient
was discharged on the 64th hospital day, having regained virtually
normal renal function.
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Discussion
DR. NisHlo HONDA (Professor and Chairman, First Depart-
ment of Medicine, Ilamamatsu University School of Medicine,
Hamamatsu, Japan): This 20-year-old patient complained of
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Fig. 1. Isoenzyme patterns of lactate dehydrogenase (LDH) in red blood cells.
severe weakness in his legs and then collapsed during a
marathon. After arriving at the hospital, the patient had muscle
pain in the thighs and diarrhea. Physical examination disclosed
fever, sweating, tachycardia, tachypnea, and depressed deep
tendon reflexes. Urinalysis revealed myoglobinuria, microhem-
aturia, proteinuria, and glucosuria. Laboratory examinations
performed the following day disclosed significant elevations in
serum CPK, LDH, and GOT levels. Myosin also was detected
in the serum. Thereafter, BUN, serum creatinine, uric acid, and
potassium concentrations increased despite the absence of
oliguria, whereas the sodium and calcium concentrations de-
creased. These findings are typical of acute renal failure follow-
ing rhabdomyolysis [11. I would like to focus my discussion on
the pathogenesis of myoglobinuric acute renal failure.
It is well known that rhabdomyolysis and myoglobinuria are
associated with acute renal failure. Skeletal muscle injuries
accompanying acute renal failure were noticed by Frankenthal
in 1916 and were described by Minami in 1923 [2]. However, it
was not until 1941 that myoglobin released from damaged
muscle cells was implicated in acute renal failure by Bywaters
and Beall [3]. In acute renal failure following rhabdomyolysis,
severe hyperkalemia and rapidly progressive azotemia develop
as a result of muscle destruction. There are additional clinical
features as well that seem to distinguish this disorder from renal
failure due to other causes.
Rhabdomyolysis
Rhabdomyolysis, the destruction of skeletal muscle, can be
associated with muscle weakness, stiffness, pain, and swelling.
Deep tendon reflexes can be depressed or absent. Rhabdomyol-
ysis is usually manifested as abnormal elevations of muscle cell
constituents in the serum or urine, such as enzymes (CPK,
aldolase, LDH, GOT) or electrolytes (potassium, phosphorus),
or as pigmenturia. In some instances, however, myoglobinuria
may not be apparent. In the patient presented, spectropho-
tometry and immunologic testing revealed pigmenturia during
the first few days after the marathon and prompted the diagno-
sis of myoglobinuria secondary to exercise-induced
rhabdomyolysis.
Pathoeenesis of rhabdomvolvsis. Rhabdomvolvsis can be
induced by numerous factors; crush injury to a limb, excessive
use of skeletal muscle, and heat-induced disorders appear to be
the most common. Rhabdomyolysis can result from prolonged,
excessive physical exertion even in healthy subjects [4—7],
although it is more frequent in individuals in poor physical
condition [6]. Alcoholism, viral infections, metabolic disorders,
myopathies, and drugs also can induce rhabdomyolysis. Hypo-
kalemia is a particularly important predisposing factor. In the
early 1970s, Knochel et al investigated the relationship between
rhabdomyolysis and potassium depletion [8—101. They demon-
strated that moderately severe hypokalemia causes an impair-
ment of muscle membrane integrity, characterized by subnor-
mal resting membrane potential [8], elevated serum CPK activi-
ty, and a suppressed ability for glycogen synthesis in muscle
[10]. If muscle is excessively exercised in a hypokalemic
individual, not only are energy stores insufficient, but vasodila-
tion is hindered because potassium ions are not released from
the contracting muscle fibers [9]. Potassium deficiency thus
induces metabolic and hemodynamic abnormalities, both of
which could be of pathogenetic importance. In patients with
hereditary deficiency of myophosphorylase [111 or phospho-
fructokinase [12], rhabdomyolysis can be induced by physical
exercise. In addition, various hereditary enzyme defects are
associated with rhabdomyolysis following exercise. In 1980, we
first described a patient with hereditary deficiency of LDH M-
subunit [131. The patient complained of painful muscle cramps
and myoglobinuria after heavy physical exercise but did not
develop acute renal failure. Clinical and biochemical analysis in
the patient and his family suggests that the enzyme defect is of
genetic origin. Details of the metabolic analyses in that unusual
patient will be presented by Dr. Y. Nishimura, who first
detected this enzyme abnormality at the Hamamatsu University
Hospital.
DR. YosHIRo NJSHIMURA (Assistant Professor, First Depart-
ment of Medicine, Hamamatsu University School of Medicine,
Hamamatsu): The patient with hereditary deficiency of LDH
M-subunit was an 18-year-old male [13]. His chief complaint
was dark brown urine induced by severe exercise, and myoglo-
binuria was diagnosed. The patient first remembered having
muscle stiffness after extreme exertion at age 10. He thought
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Fig. 2. Pedigree ofa family with LDH M-suhunit deficiency.
that the problem had increased in severity and frequency since
he was 14 years old. Laboratory data revealed a significant
elevation of serum CPK activity, up to 26,920 lU/liter. Plasma
LDH activity was only 443 lU/liter, slightly above the normal
value. The isoenzyme pattern of erythrocyte LDH was deter-
mined and revealed only one of the four moieties normally
present (Fig. 1).
In skeletal muscle, as elsewhere, LDH is the terminal en-
zyme in the sequential reaction from glycogen to lactate in
anaerohic glycolyis..This enzyme is separated into five isoen-
zymes, which are tetramers of two types of polypeptide chains,
called H- and M-subunits; these subunits are controlled by two
different genes. The LDH isoenzyme patterns in the patient's
family, determined by analysis of serum and red and white
blood cells, showed an autosomal recessive pattern of inheri-
tance of the M-subunit defect (Fig. 2). Only the homozygotes
showed an elevation in serum CPK activity.
To explore the pathogenesis of myoglobinuria following
physical exercise, we performed a forearm ischemic test in this
patient. Immediately after completion of the test, the patient
was unable to open his fist because of a painful muscle cramp;
this muscle contracture was electromyographically silent. Bio-
chemical analysis revealed a high plasma pyruvate concentra-
tion and an incomplete lactate response (Fig. 3). These findings
seem quite different from those in the glycogen storage myo-
pathies, such as deficiencies of myophosphorylase [111 and
phosphofructokinase [12].
A muscle biopsy of the quadriceps femoris was performed
immediately following 30 seconds of ischemic work with a
bicycle ergometer. Enzyme activities in muscle extract are
summarized in Table 1. The LDH activity was approximately
5% that of the normal control value. The LDH isoenzyme
pattern in the muscle was identical to that in serum and in blood
cells.
The results of kinetic studies showed that the patient's
muscle completely lacks LDH M-subunit, Glycolytic intermedi-
ates also were evaluated in the biopsied muscle (Table 2). The
lactate concentration was less than that in the control resting
muscle, Levels of glycerol 3-phosphate, glycerol, and pyruvate
in the patient's muscle were significantly increased. Also,
fructose 1,6-diphosphate and triose phosphate (the sum of
dihydroxyacetone- and glyceraldehyde 3-phosphate) were in-
creased markedly. The findings suggest that, in the patient's
muscle, the NAD-dependent oxidation of glyceraldehyde 3-
phosphate to 1,3-diphosphoglycerate might be a rate-limiting
step in glycolysis.
To examine the possibility that these metabolic abnormalities
are associated with an impairment of energy production from
glycolysis, we performed an in vitro metabolic analysis of the
muscle. Figure 4 illustrates the time course of glycolysis from
glucose 6-phosphate in the supernatant of muscle extract. A
decrease in glucose 6-phosphate was accompanied by a tran-
sient rise in fructose 6-phosphate. Fructose I ,6-diphosphate
and pyruvate concentrations increased with a lag time of
approximately 5 minutes. Lactate accumulation was only one-
third to one-fourth that of pyruvate. Massive accumulation of
glycerol 3-phosphate was found. The sum of pyruvate and
lactate formation was approximately 50% that in normal con-
trols. Furthermore, comparable amounts of glycerol 3-phos-
phate and glycerol were produced.
It is well established that glycerol 3-phosphate does not
accumulate in anaerobic glycolysis in the mammalian muscle,
as most NADH formed by glyceraldehyde 3-phosphate dehy-
drogenase can be reoxidized to NAD during the subse-
quent conversion of pyruvate to lactate. In this patient, howev-
er, the reoxidation of NADH by LDH was limited, probably
because of the defect of M-subunit. As a result, NADH
suppressed the activity of glyceraldehyde 3-phosphate dehydro-
genase through product inhibition. Next, the NADH formed
was partially reoxidized to NAD by glycerol 3-phosphate
dehydrogenase with the conversion of dihydroxyacetone-phos-
phate to glycerol 3-phosphate. Thus, it is likely that the main
course of anaerobic glycolysis in this patient was shifted toward
glycerol formation from dihydroxyacetone-phosphate, and ATP
production was significantly reduced (Fig. 5). In muscle of
normal individuals, 1 mole of glucose produces 4 moles of ATP
and consumes 1 mole through glycolysis. By contrast, in this
patient's muscle, only 2 moles of ATP might be produced,
because approximately 50% of triose phosphate was metabo-
lized to pyruvate.
I conclude that only M-subunit of LDH takes part in anaero-
bic glycolysis in working muscle; in the patient with LDH M-
subunit deficiency, insufficient ATP production by glycogen-
olysis might induce rhabdomyolysis following heavy physical
exertion. This disease may be a new genetic disorder of
anaerobic glycolysis in skeletal muscle.
DR. HONDA: As 1 mentioned, rhabdomyolysis and myoglo-
binuria occur under numerous circumstances. However, the
mechanisms ultimately responsible for rhabdomyolysis are not
always clear. In many instances there is either decreased
availability of energy substrates or an impaired capacity for
utilization of the substrates in the muscle. When metabolic
stress is superimposed, chemical processes that maintain the
integrity of the muscle membrane may be impaired, thereby
permitting leakage of muscle cell constituents into the circula-
tory system [1].
The 20-year-old patient presented today had neither pigmen-
tuna nor alcohol or drug habits. On the day of the marathon, he
had a cold. Fever, sweating, and diarrhea with resultant dehy-
dration were present when he arrived at the hospital. Mild
hypokalemia also was found, which might have resulted from
diarrhea and from losses of body potassium because of physical
exertion in a warm climate [9]. In this patient, the LDH M-
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Fig. 3. Venous blood levels of pyruvate and
lactate after forearm ischemic test in a patient
with LDH M-subunit deficiency (thick line)
and in 4 normal males of similar age (thin
lines).
subunit deficiency was not detected. The forearm ischemic test
showed an appropriate elevation of the serum lactate level, in
contrast with the response in McArdle's disease [11]. Although
further detailed metabolic analysis was not performed, exces-
sive use of skeletal muscle might have been the main cause of
the rhabdomyolysis. Also the intercurrent viral infection, dehy-
dration, or hypokalemia could have contributed to rhabdomyo-
lysis. However, we cannot completely rule out the possibility
that a metabolic disorder underlies rhabdomyolysis in this
patient.
Myoglobinemia and myoglobinuria. Myoglobin. a muscle
constituent, is a heme pigment that closely resembles hemoglo-
bin. Its molecular weight of 17,800 is approximately one-fourth
that of hemoglobin (molecular weight, 68,800). In healthy
individuals, myoglobin content in skeletal muscle is approxi-
mately 4 mg/g of wet weight [14]. In the plasma, however,
myoglobin concentration ranges from 0 to 0.003 mg/dl [14].
Fifty percent of plasma myoglobin seems to be bound to cr2-
globulin [1, 15] at myoglobin concentrations less than approxi-
mately 23 mg/dl. A renal threshold of 0.5 to 1.5 mg/dl exists for
myoglobin [16]. Therefore, myoglobin's plasma level must
exceed 1.5 mg/dl before it is excreted into the urine. At plasma
concentrations between 1.5 and 23 mg/dl, approximately 50% of
the circulating myoglobin is filtered. Before the urine becomes
discolored by myoglobin, however, the urine level of myoglobin
must exceed 100 mg/dl [1]. The following variables thus deter-
mine whether myoglobinuria is visible: (1) plasma level of
myoglobin above the renal threshold; (2) extent of the plasma
protein binding of myoglobin; (3) glomerular filtration rate; and
(4) urine flow rate [11.
Unlike hemoglobin, myoglobin is not bound to haptoglobin in
the plasma. Therefore, the plasma haptoglobin concentration
decreases in hemoglobinemia but not in myoglobinemia, as we
observed in the patient under discussion today. Myoglobin in
the plasma and urine samples is identified by means of spec-
trophotometry or immunologic techniques [17, 18].
Clinical features in rhabdomyolysis. In many patients with
rhabdomyolysis, serum creatinine concentration is dispropor-
tionately elevated with respect to the BUN [1], as in the patient
we are discussing. Such a disproportionate elevation of the
creatinine level is thought to result from an escape of massive
amounts of creatine from damaged muscle and the subsequent
transformation of that creatine into creatinine.
Significant hyperuricemia is often observed in rhabdomyoly-
sis, especially in exertional rhabdomyolysis [1], again as in this
patient. Serum uric acid concentration is inappropriately high
for the BUN level. This uric acid probably arises from hepatic
conversion of the purines released from damaged muscle cells
[1]. Following physical exertion, total uric acid production and
urinary excretion are accelerated [1].
One of the most characteristic electrolyte abnormalities in-
duced by rhabdomyolysis is severe hyperkalemia, a complica-
tion that usually appears within the first few days. Release of
potassium ions from damaged muscle cells may produce ex-
treme hyperkalemia. especially in patients with acidemia or
oliguria. When serum potassium concentration is measured
early in the course of exertional rhabdomyolysis, however,
hypokalemia is observed in approximately one-half of patients
[5].
Hypocalcemia also appears very early following rhabdomyo-
lysis and usually becomes prominent after the first 24 hours [1].
The pathogenesis of the hypocalcemia occurring in association
with rhabdomyolysis is still poorly understood [19]. Meroney et
al suggested that the reduction in serum calcium resulted from
deposition of calcium in damaged muscles, although the critical
factors influencing calcium deposition are not known [20]. On
the other hand, Llach, Felsenfeld, and Haussler hypothesized
that hypocalcemia in the oliguric phase of rhabdomyolysis-
induced renal failure may be secondary to a decreased level of
1,25 dihydroxycholecalciferol and skeletal resistance to para-
thyroid hormone, partly due to hyperphosphatemia [21]. In
contrast, this patient displayed a slightly elevated serum calci-
um concentration, presumably due to the dehydration-induced
rise in the total protein concentration. The following day, serum
calcium was normal and it decreased when acute renal failure
developed.
Phosphate leakage from damaged muscle cells causes hyper-
phosphatemia and, in turn, provokes the precipitation of calci-
um phosphate in soft tissues, blood vessels, and eyes [1].
Hyperphosphatemia also indirectly stimulates the production of
parathyroid hormone. As the bone may be resistant to effects of
parathyroid hormone in this disorder, hypocalcemia persists
despite elevated levels of the hormone [21]. In this patient,
serum phosphorus concentration remained within the normal
range during the first few days and then increased as renal
failure developed.
The patient showed mild glucosuria without hyperglycemia.
Transient glucosuria is common in patients with exertional
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Hexokinase 0.24 0.51
Aldolase 80 95
TP1' 1927 1489
GA3PDHC 141 100
GPDHd 24 15
LDH II 226
GOT 58 52
GPT 3 5
CPK 2964 2332
rhabdomyolysis and probably reflects proximal tubular injury
[141.
Most patients with rhabdomyolysis show evidence of dissem-
inated intravascular coagulation (DIC), which might contribute,
in part, to a reduction in renal blood flow and glomerular
filtration rate. It is not clear, however, whether DIC results
from a liberation of thromboplastin from damaged muscle [221.
Although the platelet count was reduced, this patient did not
have DIC; fibrin degradation products were not detected in
blood or urine, and the plasma fibrinogen concentration re-
mained within the normal range.
Pathophysiology of myoglobinuric acute renal failure
The clinical data showed that acute renal failure occurred
following rhabdomyolysis in our patient. It is well known that
skeletal muscle injury and myoglobinuria are associated with
acute renal failure.
Nephrotoxicity of myoglohin and other muscle constituents.
Bywaters and Stead [23] and subsequent investigators [22, 24]
have suggested that myoglobin and other constituents of the
muscle cell impair renal function. However, a controversy
exists regarding the nephrotoxicity of myoglobin itself. In some
instances, myoglobinemia does not induce acute renal failure
[16]. Many studies have suggested that myoglobin itself is
relatively nonnephrotoxic but that it becomes highly toxic when
dehydration, acidemia, or both coexist [25—27]. These data
indicated that aciduria is a prerequisite for myoglobin nephro-
toxicity and, furthermore, that dehydration and a concentrated
urine potentiate the nephrotoxic effect of myoglobin in the
presence of an acid urine. At or below a urine pH of 5.6, both
myoglobin and hemoglobin produce ferrihemate (hematin) [28],
which seems to be toxic to the kidney as well as to the vascular
and reticuloendothelial systems [24, 29]. Furthermore, in exer-
tional rhabdomyolysis with myoglobinuria and increased uric
acid excretion, ferrihemate and uric acid may precipitate in
concentrated, acidic urine and thus impair renal function [1].
Controversy exists concerning the effect of myoglobin itself on
renal hemodynamics [22, 27]. It is known, however, that
intravenously administered muscle extracts decrease systemic
blood pressure and glomerular filtration rate [22].
Animal models of myog!ob7nuric renalfailure. Animal mod-
Table 2. Glycolytic intermediates in skeletal muscle
Patient Control
G6Pb 25
F6P 25
FDPd 370
DRAPe 540
GA3P 127
Glycerol-3P5 899
Glycerol 1780
Pyruvate 311
Lactate 1340
a
nanomoles/g wet weight.
G6P refers to D-glucose-6-phosphate.
F6P refers to D-fructose-6-phosphate.
FDP refers to D-fructose- I ,6-diphosphate.
DHAP refers to dihydroxyacetone-phosphate.
GA3P refers to glyceraldehyde-3-phosphate.
Glycerol-3P refers to glycerol-3-phosphate.
els of myoglobinuric acute renal failure have been produced via
intravenous injection of myoglobin along with additional proce-
dures such as dehydration and metabolic acidosis, or by intra-
muscular or subcutaneous injection of hypertonic glycerol
solution. Although this form of myoglobinuric acute renal
failure is not completely comparable to that in humans, these
models have been used widely for exploring the pathogenesis of
renal failure. Garcia et al demonstrated that intravenous infu-
sion of myoglobin in rats produces an early, consistent fall in
glomerular filtration rate under a variety of conditions [27]. A
greater reduction in GFR occurred in animals subjected to prior
dehydration. These authors also noted that intratubular cast
formation was increased by a low urine pH, once again incrimi-
nating ferrihemate.
Intravenous injection offerrihemate produced glomerular and
tubular damage [29]: glomerular tufts showed hyaline thrombi,
cellular proliferation, and occasionally leukocyte infiltration.
Degeneration of the tubules varied from mild swelling to
extensive necrosis. Casts also were observed in the kidney with
severe tubular injury.
Braun and associates found that the subcutaneous injection
of hypertonic glycerol solution produces both hemolysis and
rhabdomyolysis in hydropenic rats and provokes fluid accumu-
lation at the injection site [24]. This fluid accumulation accentu-
ates the circulatory effects of prior dehydration. Six hours after
glycerol injection, the proximal tubules, loops of Henle, and
collecting tubules become plugged with pigment casts and
cellular debris [301. After 24 hours, a7otemia and proximal
tubular necrosis were present [30, 31].
Mechanisms ofrenal failure. Controversy still exists regard-
ing the detailed mechanisms responsible for the development of
acute renal failure in myoglobinuria as in other clinical settings
associated with so-called acute tubular necrosis. Suggested
mechanisms for producing and maintaining renal failure in-
clude: (1) a primary reduction of glomerular filtration rate due
to cortical and glomerular hemodynamic changes or to reduced
glomerular permeability; (2) tubular obstruction by casts; and
(3) back-leakage of filtrate across damaged tubular epithelia.
REDUCED GLOMERULAR FILTRATION RATE. Some investiga-
tors have suggested that increased renal vascular resistance and
reduced cortical blood flow play an important role in the
Table 1. Enzyme activities in supernatants
of muscle extractsa
Patient Control
zmoles/min/g wet tissue weight.
TPI refers to triosephosphate isomerase.
GA3PDH refers to glyceraldehyde 3-phosphate
dehydrogenase.
d GPDH refers to 3-phosphoglycerol dehydrogenase.
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Fig. 4. Time course of glycolysis from glucose 6-phosphate (GOP) in the
supernatant of muscle extracts from a patient with LDH M-subunit
deficiency. F6P refers to fructose-6-phosphate; FDP refers to fructose
diphosphate; a-GP refers to alpha glycerol phosphate; Pyr refers to
pyruvate; Lact refers to lactate.
diminution of glomerular filtration and the development of
acute renal failure [32—35]. Accumulating evidence indicates,
however, that the pathogenetic role of renal hemodynamic
alterations may differ with different models and at different
stages of renal failure [36]. For example, renal ischemia is not
always necessary for the development and maintenance of
nephrotoxic renal failure [37, 38].
In the initial stages of glycerol-induced renal failure, a
significant increase in renal vascular resistance with a recipro-
cal reduction in renal blood flow has been uniformly demon-
strated. Ayer et al demonstrated that renal blood flow fell to
81% of control in rats within 10 minutes after intramuscular
glycerol injection, and fell further to 27% of control at 24 hours
[331. This decrease in blood flow was accompanied by redistri-
bution of the regional blood flow from the outer to the inner
cortex. Morphologic examination revealed both afferent and
efferent vasoconstriction in the kidneys of rats with myohemo-
globinuric acute renal failure [39]. More important, acute vol-
ume loading with Ringer's solution attenuated the reduction in
renal blood flow and glomerular filtration rate in the first 3
hours after glycerol administration [40]. These findings suggest
a critical role for reduced renal blood flow in the suppression of
glomerular filtration rate in the early stages of glycerol-induced
renal failure.
The level of renal blood flow 24 to 48 hours after the initiation
of renal failure is variable in the glycerol model; normal levels
or persistent reductions in blood flow have been observed [33,
35, 41]. In contrast with the initial stage, some 18 hours after
glycerol administration, volume loading with Ringer's solution
did not improve the glomerular filtration rate despite a restora-
tion of renal blood flow to or above a normal level [40]. These
findings suggest that renal ischemia plays only a minor role in
the maintenance of renal failure in this model.
Mediators of the initial renal vasoconstriction in myoglobinu-
nc acute renal failure have not been clearly established, but the
following have been proposed: (1) increased sympathetic nerve
activity; (2) activated renin-angiotensin system; (3) suppressed
renal prostaglandin synthesis; (4) elevated plasma level of
vasopressin; and (5) glomerular microthrombi. In the glycerol
model of acute renal failure in the rat, McLean and Thomson
demonstrated that prior administration of phenoxybenzamine
lessens the renal functional impairment and morphologic dam-
age but does not prevent the development of renal failure [421.
The findings suggest a partial contribution of increased sympa-
thetic nerve activity to renal vasoconstriction.
In 1945, Goormaghtigh first described increased granularity
of the juxtaglomerular cell in patients with anuric crush injury
and suggested a role for vasopressor substance liberated from
the cell in arteriolar spasm [43]. Since then, numerous studies
have explored the role of the renin-angioten sin system in acute
renal failure. It is well known that plasma renin activity
increases in the oliguric stage of both experimental and clinical
acute renal failure, but that it is not elevated in the diuretic stage
[44—46]. Using the rat model of glycerol-induced renal failure,
McDonald et al noted that long-term saline loading attenuates
the renal functional impairment, and they suggested that this
protective effect might be due to a diminution of intrarenal renin
content [47]. These observations support the view that the
renin-angiotensin system is involved in the pathogenesis of
acute renal failure. Increased activity of the renin-angiotensin
system may provoke initial renal vasoconstriction and reduc-
tion in glomerular filtration through direct action on the renal
blood vessels, effects on angiotensin II receptors in the glomer-
ulus [48], a tubuloglomerular feedback mechanism [49], or all of
these combined. Recent evidence seems to argue against a
causative role for the renin-angiotensin system, however. First,
plasma renin activity usually returns to normal even though
renal failure persists. Second, immunization against renin in
rats can suppress a pressor response to an infusion of exoge-
nous renin, but it does not protect against the development of
mercuric chloride- or glycerol-induced renal failure [50]. Similar
results were obtained with active and passive immunization
against angiotensin II [51]. Third, Ishikawa and Hollenberg
found that an angiotensin II antagonist and an angiotensin
converting enzyme inhibitor increase renal blood flow 3 hours
after glycerol injection, but that they do not prevent the
elevation of blood urea nitrogen concentration [52].
Why are chronically salt-loaded animals resistant to acute
renal failure? A saline load not only suppresses the activity of
the renin-angiotensin system but also induces an increase in
urinary solute and water excretion. Bidani, Churchill, and
Fleischmann noted that the prevention of nephrotoxic acute
renal failure by chronic saline loading is independent of sup-
pressed activity of the renin-angiotensin system [53]. Cronin et
al [541 and Patak and associates [55] demonstrated that the
prevention of norepinephrine-induced renal failure by prosta-
glandin E2, bradykinin, furosemide, or mannitol is related to an
increase in urinary solute excretion rather than to increased
renal blood flow. These findings suggest that a chronic saline
load protects against the development of acute renal failure
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M-subunit deficiency (right). Glycolysis in the
patient's muscle does not yield efficient ATP,
possibly because considerable amounts of
glycogen-derived carbon and hydrogen are
converted to glycerol 3-phosphate.
through an elevation of intratubular pressure and the prevention
of tubular obstruction by enhanced urinary solute and water
excretion, and not through suppressed activity of the renin-
angiotensin system. These data also indicate that suppression of
the renin-angiotensin system does not substantially influence
the course or outcome of acute renal failure, even though early
renal vasoconstriction can be caused by increased activity of
this system.
Several studies have suggested that prostaglandins contribute
to the development of acute renal failure [56—58]. Reduced
prostaglandin synthesis probably increases renal vasoconstric-
tion in acute renal failure, as the vasodilator prostaglandins
counterbalance the vasoconstrictive effect of angiotensin II.
Torres and associates [57] and Solez et al [581 demonstrated in
rabbits that indomethacin, a prostaglandin synthetase inhibitor,
increases the incidence and severity of glycerol-induced renal
failure, but that it fails to aggravate mercuric chloride-induced
renal failure. In contrast, the vasodilator prostaglandin A did
not alter the course or outcome of glycerol- or uranyl nitrate-
induced renal failure in rats [59].
Endogenous vasopressin also has been implicated as a media-
tor of renal ischemia in myoglobinuric acute renal failure.
According to Hofbauer et a!, the plasma vasopressin level
increases 40-fold two hours after glycerol injection [601. This
level exceeds that needed to induce vasoconstriction. Although
glycerol injection induces acute renal failure even in rats with
diabetes insipidus, the severity of renal failure in animals
lacking vasopressin was intermediate between that induced by
glycerol in nondehydrated and that induced in severely dehy-
drated animals [611. Furthermore, administration of exogenous
vasopressin in a dose necessary to cause a vascular effect
increased the severity of experimental acute renal failure [621.
These findings suggest that endogenous vasopressin contributes
to renal vasoconstriction in myoglobinuric renal failure.
Glomerular microthrombi resulting from DIC also might
contribute to renal hemodynamic alterations. Blachar et al
demonstrated that infusion of muscle extracts in rabbits induces
a fall in systemic blood pressure concomitant with a reduction
in glomerular filtration rate [22]. In these animals, glomerular
microthrombi are demonstrated regularly. Although renal blood
flow was not measured in these experiments, reduced renal
blood flow secondary to a fall in pressure and to microthrombi
might have contributed, at least in part, to the diminution in
glomerular filtration rate.
One of the other mechanisms possibly responsible for a
reduction in glomerular filtration rate in acute renal failure is a
decrement in glomerular permeability (hydraulic conductivity
multiplied by filtration area) [63—651. Unfortunately, little infor-
mation is available concerning glomerular permeability in
myoglobinuric acute renal failure. Recent evidence suggests
that angiotensin II and vasopressin reduce glomerular perme-
ability through contraction of the glomerular mesangial cells
[65]. Thus, we cannot rule out that an activated renin-angioten-
sin system and an elevated plasma vasopressin level reduce
glomerular permeability even in myoglobinuric renal failure.
Morphologic observation disclosed swelling of the glomerular
epithelial and mesangial cells between 30 minutes and 16 hours
following glycerol injection, but normal glomerular structure
within 24 hours [661. These findings support the speculation that
reduced glomerular permeability contributes to the initial fall in
glomerular filtration, even in myoglobinuric renal failure.
TUBULAR OBSTRUCTION. A prominent histologic finding in
myoglobinuric acute renal failure is tubular obstruction by
cellular debris and pigmented casts [3, 301. In rhabdomyolysis,
ferrihemate and uric acid precipitate in concentrated acidic
urine [1]. Tubular obstruction can lead to a reduction in
glomerular filtration either by elevating tubular pressure and
causing a subsequent reduction in the hydrostatic pressure
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gradient across the glomerular capillary wall, or by a preglomer-
ular vasoconstrictive response to the tubular blockade [67]. It is
not well established, however, whether tubular obstruction is a
primary cause of decreased glomerular filtration rate in acute
renal failure. Oken, Arce, and Wilson showed low proximal
intratubular pressure in the absence of tubular obstruction
within the first 4 hours of glycerol-induced renal failure [32]. On
the other hand, Stein, Lifschitz, and Barnes found intra-
tubular pressure to be uniformly normal from 3 to 18 hours after
glycerol injection; they also noted that glomerular filtration rate
is reduced markedly [36]. They did not detect dilated superficial
proximal tubules or casts in the surface nephrons. After volume
loading with Ringer's solution, however, they did observe a
modest amount of cellular debris traversing the collecting ducts
and exiting from the ducts of Bellini. Garcia et al demonstrated
cast precipitates of myoglobin and Tamm-Horsfall glycoprotein
in medullary collecting ducts in dehydrated rats 70 minutes after
infusion of myoglobin [271. They concluded that cast formation
is not important in the initial fall in glomerular filtration rate but
may be important in the maintenance of acute renal failure. It is
likely, therefore, that intratubular casts partially obstruct urine
flow in the distal nephron, although cast formation might not
play a fundamental role in the initial fall in glomerular filtration
rate.
BACK-LEAKAGE OF FILTRATE. In 1929, Richards first suggest-
ed from direct observations in mercuric chloride-poisoned frogs
that oliguric renal failure might result from the back-diffusion of
filtrate across damaged tubular epithelium [68]. Experimental
findings seem consistent with this view in some models of renal
failure, especially nephrotoxic models [64, 69—711. Bywaters
and Beall observed tubular necrosis, pigmented casts, and
interstitial edema in the kidneys of patients with anuric crush
syndrome [3]. In animals with glycerol-induced renal failure,
necrosis was found in the proximal tubules 24 hours after the
injection [30, 31]. It is possible, therefore, that a back-leakage
of filtrate might contribute to oliguria in myoglobinuric renal
failure, but scant evidence is available to support such a role.
Oken, Arce, and Wilson found no definite evidence of tubular
leakage as the primary cause of renal failure [32]. Also, microin-
jection of marker substances into the proximal tubule showed
only a small reduction in the recovery of these substances from
the distal tubule in animals with the methemoglobinuric model
of acute renal failure [72]. These findings suggest that back-
leakage of filtrate accounts for only a small portion of the
reduction in glomerular filtration rate in this model.
Questions and answers
Da, KEIJI SuzuKI (Instructor, First Department of Medicine,
University of Tokyo Faculty of Medicine, Tokyo): Dr. Honda,
you mentioned the possible adverse effects of hematin on renal
function. What specific aspects of renal function does hematin
influence?
DR. HONDA: Some investigators have shown that the uptake
of tetraethylammonium (TEA) and hippurate is suppressed in
renal cortical slices obtained from animals given subcutaneous
glycerol injection [24]. Also, myoglobin and ferrihemate sup-
press the accumulation of hippurate in cortical slices obtained
from normal rats [24]. It is also known that hematin adminis-
tered intravenously can cause a variety of changes including
dilation, hemorrhage, and microthrombi in small vessels, and
cell infiltration, proliferation, and fibrin deposition in glomeruli
[29]. These vascular events as well as direct tubular toxicity
may be involved, in part, in the pathogenesis of acute renal
failure associated with rhabdomyolysis.
DR. JORDAN J. COHEN: As you pointed out, glycerol injection
causes the release of many substances in addition to myoglobin
from the damaged muscle, any one of which might be damaging
to the kidney. The analogy with intravascular hemolysis and
hemoglobinuric" acute renal failure is evident. We know that
pure hemoglobin injected intravenously has no damaging effect
on the kidney, the implication being that other factors are
involved in mediating renal injury. Is this true for myoglobin as
well? If one gives pure myoglobin to animals or humans, does
nephrotoxicity occur?
DR. HONDA: Controversy exists concerning the nephrotoxi-
city of myoglobin. Blachar et al demonstrated in rabbits that the
intravenous injection of muscle extract, but not purified myo-
globin, decreases blood pressure, reduces GFR, and produces
microthrombi in the glomerular capillaries [22]. In contrast,
Garcia and coworkers found that the intravenous injection of
myoglobin in rats produces an early reduction in GFR under a
variety of conditions [27]. This fall in GFR was further aug-
mented by prior dehydration.
DR. TOSHIKAZU TAKABATAKE (Instructor, First Department
of Internal Medicine, Kanazawa University School of Medi-
cine, Kanazawa): You mentioned the importance of vasocon-
striction in the initial stage of myoglobinuric acute renal failure
and suggested that myoglobin per se may not cause renal failure
unless other factors such as dehydration and acidemia are
present. From your answer to Dr. Cohen's question, you seem
to leave open the possibility that some other substance released
by muscle might first sensitize the kidney to myoglobin's
action. Reasoning from experience with the hepatorenal syn-
drome, I suspect there might be substances other than sodium
chloride that activate tubuloglomerular feedback. Is it possible
that muscle extracts contain substances that stimulate the
tubuloglomerular feedback system?
DR. HONDA: I do not think that the experimental models
presently available, whether they employ glycerol or myoglo-
bin, duplicate precisely the pathogenesis of acute renal failure
associated with rhabdomyolysis in humans. In my opinion,
glycerol-induced acute renal failure in animals is a model in
which changes in renal hemodynamics are of predominant
importance. Although data suggest that renal blood flow does
decrease in patients with myogloburinuric acute renal failure, it
is not known whether the magnitude of the renal hemodynamic
changes in these patients parallels the alterations in experimen-
tal animals. I am skeptical about the nephrotoxicity of myoglo-
bin per se and think that other conditions and/or substances
must contribute to the pathogenesis of renal failure. The
persistently normal renal function in the patient with LDH
deficiency whom Dr. Nishimura discussed supports the hypoth-
esis that release of myoglobin per se is insufficient to cause
acute renal failure.
I agree with your observation that substances other than
sodium chloride can activate tubuloglomerular feedback and
that the presence of such substances might contribute to the
hepatorenal syndrome. I do not know whether administration of
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muscle extracts stimulates the tubuloglomerular feedback
mechanism.
DR. MITSUMASA NAGASE (Assistant Profrssor of Medicine,
First Department of Medicine, Hamamatsu University School
of Medicine, Ilamamatsu): What is the half-life of myoglobin in
plasma, and what factors are known to affect it?
DR. HONDA: The half-life of myoglobin in the circulation
varies between 1 and 3 hours; myoglobin completely disappears
from the plasma in approximately 6 hours [1]. As I mentioned,
there is a "renal threshold" for myoglobin excretion and, at
plasma concentrations above this threshold, urinary excretion
is a route of myoglobin removal. Also, myoglobin is catabolized
by the kidney [73]. Thus, the plasma half-life of myoglobin is
prolonged in renal failure. When myoglobin is administered in
small quantities, most of it is taken up by the reticuloendothelial
system. I am not aware of any factor that can accelerate the
disappearance of myoglobin from the plasma.
DR. HIROSHI NIHET (Chief, Kidney Center, Toranomon Gen-
eral Hospital, Tokyo): You noted the potential importance of
hematin as a pathogenetic factor in patients with rhabdomyoly-
sis and acute renal failure. Do you think hematin produced in
acidic tubular urine plays a role in initiating and maintaining the
low GFR via direct effects on renal hemodynamics?
DR. HONDA: Although intratubular hematin might be impor-
tant in promoting tubular cast formation or tubular cell damage,
I do not think that intratubular hematin directly affects hemody-
namics in humans. As far as I know, no dramatic hemodynamic
alterations can be attributed to intratubular hematin per se in
patients with brisk intravascular hemolysis, as in malaria or
congenital hematoporphyria. In extreme conditions, such as
those that can be produced in experimental animals, an acute
injection of hematin can cause hemodynamic changes, but I do
not believe such conditions apply in patients with hemoglobin-
uric or myoglobinuric acute renal failure.
DR. NIHE!: I am also curious to know whether angiotensin
could play a role, either through its hemodynamic effect or
through its action on glomerular permeability via mesangial
contraction.
DR. HONDA: lam not certain about the role of angiotensin. It
is impossible to examine separately the actions of this sub-
stance on glomerular arterioles, glomerular mesangium, and
tubuloglomerular feedback. As you know, glomerular perme-
ability, so-called Kf, is determined by both the filtration surface
area and the true hydraulic conductivity. Any fall in glomerular
permeability thus may be due to a reduction in true permeability
or filtration surface area or both. Schor and associates suggest-
ed that the fall in glomerular permeability in gentamicin-induced
acute renal failure results from a diminished surface area
through angiotensin-mediated contraction of mesangial cells
[65]. Moreover, in their experiments an angiotensin converting
enzyme inhibitor prevented a fall in glomerular filtration rate.
DR. MASAO SHIBATA (Associate Profrssor, Department of
Medicine, Nagoya University Branch Hospital, Nagoya): You
mentioned the possible role of thrombi in the glomerulus as a
factor contributing to myoglobinuric acute renal failure, Do you
know whether this mechanism was operative in the patient we
are discussing today?
DR. HONDA: We had no clear evidence for the presence of
DIC. Although the platelet count was decreased, neither the
urine nor the plasma contained fibrin degradation products, and
the plasma fibrinogen level was normal. Thus, if glomerular
thrombi were present in this patient, they probably were not
extensive.
DR. Cot-tEN: Dr. Nishimura, why do you think patients with
metabolic disorders such as McArdle's disease develop acute
renal failure so infrequently?
DR. NIsHIMuRA: Histologic examination of muscle obtained
from patients with McArdle's disease or other enzyme deficien-
cies reveals only minor localized or focal degenerative changes
coupled with transient local swelling for 24 to 48 hours follow-
ing exercise. On the basis of these morphologic changes, one
can surmise that the leakage of muscle constituents into the
circulation may be quite limited, both quantitatively as well as
qualitatively. By contrast, in cases of acute rhabdomyolysis
such as that occurring with crush injury, muscle necrosis is
extensive and undoubtedly results in significant release of all
the constituents of muscle into the circulation. Such differences
may well be important in the genesis of acute renal failure, as
Dr. Honda suggested.
DR. HONDA: In addition, I imagine that these patients avoid
intense physical exercise because of the discomfort they experi-
ence. This inactivity also would tend to reduce the frequency of
myoglobinuric acute renal failure in these patients.
DR. KIY05HI KUROKAWA (Professor of Medicine, UCLA
School of Medicine, and Chief Nephrology Section, Veterans
Administration Wadsworth Hospital, Los Angeles, California):
Patients with carnitine palmityl transferase deficiency develop
acute rhabdomyolysis and myoglobinuria after physical exer-
cise only when they are fasted and not when they are fed [74].
Patients with this condition do not need to restrict their physical
activity as long as they eat just before they exert themselves.
This distinction may be very important for athletes. With this in
mind, would you routinely suggest muscle biopsy and appropri-
ate enzyme assays in all patients with idiopathic rhabdomyoly-
sis, such as the patient we discussed?
DR. HONDA: It depends on the level of suspicion. If it is very
low, I would not recommend biopsy. If the suspicion is moder-
ately high, for example, if myoglobin turns up in the urine or if
the patient has had an episode of myoglobin-induced acute renal
failure, then the physician should consider the possibility of an
underlying metabolic or enzyme defect or a combination of the
two. In such cases a muscle biopsy may be of considerable
value because identification of one of these disorders could help
these patients or other members of their families avoid repeated
episodes of rhabdomyolysis.
DR. COHEN: Are there any special considerations regarding
the treatment of patients who have myoglobinuric acute renal
failure?
DR. HONDA: I would stress the following points. First, in
rhabdomyolysis associated with exertion, marked dehydration
may be present that may lead to shock. Aggressive fluid
replacement with saline is therefore essential. This patient was
given only 1.5 liters of saline intravenously during the initial few
hours; I suspect this amount was insufficient. Second, because
hyperkalemia is more common and more severe in myoglobin-
uric acute renal failure, early administration of Kayexalate is
prudent. Some have suggested that administration of glucose
and insulin is not as effective as one might expect in patients
with extensive muscle necrosis. In addition, administration of
calcium salts for the treatment of hyperkalemia should be
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undertaken very carefully if at all in these patients, because it
can accentuate calcium deposition in the necrotic muscle.
Third, after restoration of body fluids, one can give mannitol,
furosemide, or both intravenously in an attempt either to
mitigate acute renal failure or to convert oliguric to nonoliguric
renal failure. Urinary alkalinization with sodium bicarbonate or
sodium lactate is reasonable but should be done carefully if at
all in view of the risks entailed. In patients whose urine flow
increases in response to mannitol or furosemide, urine pH is
usually above 6, obviating the need for alkali administration.
Fourth, fasciotomy may be required when extensive muscle
necrosis is present because in a tight fascial compartment
muscle swelling can impair circulation and cause further muscle
necrosis. Fifth, aggressive use of phosphate-binding antacids
may be needed to control marked hyperphosphatemia. Sixth,
hypocalcemia often requires no treatment because it tends to
correct itself. The same is true of DIC, if present. There is little
evidence that heparin shortens the course or improves the
prognosis of acute renal failure secondary to rhabdomyolysis.
Seventh and last, both hemodialysis and peritoneal dialysis are
effective in these patients.
Reprint requests to Dr. N. Honda, First Department of Medicine,
Hamamatsu University School of Medicine, 3600 Handa-cho, Hama-
matsu 431—31, Japan
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